Compare VVOS & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VVOS | CVKD |
|---|---|---|
| Founded | 2016 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.4M | 20.7M |
| IPO Year | 2020 | 2023 |
| Metric | VVOS | CVKD |
|---|---|---|
| Price | $2.07 | $12.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $6.25 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 123.1K | 43.2K |
| Earning Date | 11-19-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,317,000.00 | N/A |
| Revenue This Year | $17.96 | N/A |
| Revenue Next Year | $55.64 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.76 | N/A |
| 52 Week Low | $1.98 | $8.12 |
| 52 Week High | $7.95 | $22.90 |
| Indicator | VVOS | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 38.11 | 59.00 |
| Support Level | $1.98 | $9.55 |
| Resistance Level | $2.28 | $12.00 |
| Average True Range (ATR) | 0.13 | 0.94 |
| MACD | 0.02 | 0.34 |
| Stochastic Oscillator | 25.71 | 93.88 |
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.